Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC Filings

SEC Filings

Filing date Form Description View
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML

Pagination